Search

Your search keyword '"Khurshid, Humera"' showing total 11 results
Start Over Author "Khurshid, Humera" Publication Year Range Last 3 years
11 results on '"Khurshid, Humera"'

1. Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update

Author

Kalemkerian, Gregory P., Khurshid, Humera, Ismaila, Nofisat, Khurshid, Humera, Ismaila, Nofisat, Bian, Jessica, Dabney, Raetasha, Das, Millie, Ellis, Peter, Feldman, Jill, Hann, Christine L., Kulkarni, Swati, Laskin, Janessa, Manochakian, Rami, Mishra, Deebya Raj, Preeshagul, Isabel, Reddy, Pavan, Saxena, Ashish, Weinberg, Frank, and Kalemkerian, Gregory P.

Published
2024
Full Text
View/download PDF

4. NeoRad(Low): A phase 2 trial of neoadjuvant (NA) ipilimumab + nivolumab (ipi+nivo) with low dose stereotactic body radiation therapy (SBRT) as an immune stimulant in patients with resectable stage IB-III non-small cell lung cancer (NSCLC).

Author

DiPetrillo, Thomas A., primary, Garcia-Moliner, Maria, additional, Koffer, Paul, additional, Hepel, Jaroslaw T., additional, Khan, Hina, additional, Khurshid, Humera, additional, Abbas, Abbas, additional, Birnbaum, Ariel E., additional, Olszewski, Adam J., additional, Ferreira, Cheyenne, additional, Hassinger, Faith, additional, Carlin McCormick, Michele, additional, Giesing, Hannah, additional, Rodrigues, Nuno, additional, Rosati, Vallerie, additional, Wood, Roxanne, additional, Webber, Amy, additional, Maleki, Sara, additional, and Azzoli, Christopher G., additional

Published
2024
Full Text
View/download PDF

6. Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline

Author

Khurshid, Humera, primary, Ismaila, Nofisat, additional, Bian, Jessica, additional, Dabney, Raetasha, additional, Das, Millie, additional, Ellis, Peter, additional, Feldman, Jill, additional, Hann, Christine, additional, Kulkarni, Swati, additional, Laskin, Janessa, additional, Manochakian, Rami, additional, Mishra, Deebya Raj, additional, Preeshagul, Isabel, additional, Reddy, Pavan, additional, Saxena, Ashish, additional, Weinberg, Frank, additional, and Kalemkerian, Gregory P., additional

Published
2023
Full Text
View/download PDF

9. BrUOG 387: Phase Ib investigator-initiated trial of a heat shock protein 90 inhibitor (HSP90i) combined with a CDK4/6i in advanced breast cancer progressing on CDK4/6i and in solid tumors with retinoblastoma (Rb)-deficiency (IND163592).

Author

El-Deiry, Wafik S., Graff, Stephanie L., Azzoli, Christopher G., Dizon, Don S., Fenton, Mary Anne, Sikov, William M., Safran, Howard, Khan, Hina, Khurshid, Humera, Schumacher, Andrew, Zhou, Lanlan, Zhao, Shuai, Seyhan, Attila A., Ryspayeva, Dinara, Wood, Roxanne, Winer, Arthur, Calleja, Elizabeth Martine, and Ross, Eric A.

Published
2023
Full Text
View/download PDF

10. Assessment of Frailty and Risk of Chemotherapy Toxicity at a Geriatric-Oncology Multidisciplinary Clinic.

Author

RAZA, SAKEENA, RUDOLPH, JAMES L., MUJAHID, NADIA, ZHOU, EMILY, NEUPANE, IVA, MONTEIRO, JOAO FILIPE G., SINGH, MRIGANKA, and KHURSHID, HUMERA

Subjects
*RISK assessment, *CANCER chemotherapy, *GERIATRIC assessment, *FRAILTY, *BREAST cancer
Abstract

BACKGROUND: Multidisciplinary Geriatric-Oncology (GO-MDC) clinic performed comprehensive geriatric assessment (CGA) to determine frailty and chemotherapy toxicity risk. METHOD: Retrospective cohort study of patients ≥65 years seen between April 2017 to March 2022. We compared Eastern Cooperative Oncology Group-Performance Status (ECOG-PS) to CGA as a determinant of frailty and risk of toxicity from chemotherapy. RESULTS: Mean age of the 66 patients was 79 years. Eighty-five percent were Caucasian. Predominant cancers were breast (30%), and gynecological (26%). One-third were stage 4. The CGA identified fit (35%), vulnerable (48%), and frail (17%) patients whereas ECOG-PS classi- fied 80% as fit. CGA assessed 57% of ECOG-fit patients as vulnerable or frail (p<0.001). High chemotherapy toxicity risk using CGA was 41% and using ECOG was 17% (p=0.002). CONCLUSION: At GO-MDC, CGA was a better predictor of frailty and toxicity risk than ECOG-PS. Treatment modification was recommended in one-third of patients. [ABSTRACT FROM AUTHOR]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results